Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-14 pm EDT 		5-day change 1st Jan Change
67.65 USD +0.16% Intraday chart for Gilead Sciences, Inc. +3.35% -16.49%
May. 09 Declaration of Voting Results by Gilead Sciences CI
May. 09 Declaration of Voting Results by Gilead Sciences CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 82,209 73,031 91,081 107,677 100,942 84,282 - -
Enterprise Value (EV) 1 82,450 103,910 118,530 126,522 118,665 102,434 96,967 91,819
P/E ratio 15.4 x 583 x 14.7 x 23.6 x 18 x 194 x 13.1 x 12.3 x
Yield 3.88% 4.67% 3.91% 3.4% 3.7% 4.57% 4.8% 4.99%
Capitalization / Revenue 3.66 x 2.96 x 3.34 x 3.95 x 3.72 x 3.05 x 3.01 x 2.93 x
EV / Revenue 3.67 x 4.21 x 4.34 x 4.64 x 4.38 x 3.71 x 3.47 x 3.2 x
EV / EBITDA 6.61 x 7.88 x 8.12 x 8.86 x 9.01 x 10.7 x 6.95 x 6.51 x
EV / FCF 9.91 x 13.8 x 11 x 15.2 x 16 x 12.3 x 9.96 x 9.14 x
FCF Yield 10.1% 7.24% 9.12% 6.59% 6.25% 8.16% 10% 10.9%
Price to Book 3.65 x 4.04 x 4.32 x 5.05 x 4.48 x 4.25 x 3.55 x 3.14 x
Nbr of stocks (in thousands) 1,265,146 1,253,528 1,254,384 1,254,244 1,246,042 1,245,853 - -
Reference price 2 64.98 58.26 72.61 85.85 81.01 67.65 67.65 67.65
Announcement Date 2/4/20 2/4/21 2/1/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 22,449 24,689 27,305 27,281 27,116 27,600 27,983 28,735
EBITDA 1 12,468 13,184 14,598 14,283 13,177 9,607 13,949 14,094
EBIT 1 11,064 11,704 12,548 12,180 10,484 7,345 11,604 12,025
Operating Margin 49.29% 47.41% 45.95% 44.65% 38.66% 26.61% 41.47% 41.85%
Earnings before Tax (EBT) 1 5,160 1,669 8,278 5,814 6,859 1,509 8,279 8,664
Net income 1 5,386 123 6,225 4,592 5,665 403.5 6,354 6,807
Net margin 23.99% 0.5% 22.8% 16.83% 20.89% 1.46% 22.71% 23.69%
EPS 2 4.220 0.1000 4.930 3.640 4.500 0.3487 5.161 5.509
Free Cash Flow 1 8,319 7,518 10,805 8,344 7,421 8,358 9,732 10,043
FCF margin 37.06% 30.45% 39.57% 30.59% 27.37% 30.28% 34.78% 34.95%
FCF Conversion (EBITDA) 66.72% 57.02% 74.02% 58.42% 56.32% 87.01% 69.77% 71.26%
FCF Conversion (Net income) 154.46% 6,112.2% 173.57% 181.71% 131% 2,071.73% 153.17% 147.55%
Dividend per Share 2 2.520 2.720 2.840 2.920 3.000 3.092 3.245 3.373
Announcement Date 2/4/20 2/4/21 2/1/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 7,244 6,590 6,260 7,042 7,389 6,352 6,599 7,051 7,115 6,686 6,720 6,977 7,239 6,484 6,781
EBITDA 1 2,042 4,049 3,195 3,811 3,227 2,883 3,258 3,908 3,427 - 3,365 3,541 3,543 - -
EBIT 1 1,507 3,524 2,670 3,286 2,699 2,243 2,277 3,224 2,739 -1,117 2,683 2,891 2,913 2,605 2,729
Operating Margin 20.8% 53.47% 42.65% 46.66% 36.53% 35.31% 34.51% 45.72% 38.5% -16.71% 39.93% 41.44% 40.24% 40.17% 40.25%
Earnings before Tax (EBT) 1 759 -152 1,503 2,432 2,031 1,300 1,588 2,318 1,653 -4,486 1,789 2,106 2,207 2,197 2,270
Net income 1 382 19 1,144 1,789 1,640 1,010 1,045 2,180 1,429 -4,170 1,365 1,596 1,651 1,651 1,732
Net margin 5.27% 0.29% 18.27% 25.4% 22.2% 15.9% 15.84% 30.92% 20.08% -62.37% 20.31% 22.88% 22.81% 25.47% 25.54%
EPS 2 0.3000 0.0200 0.9100 1.420 1.300 0.8000 0.8300 1.730 1.140 -3.340 1.101 1.273 1.310 1.240 1.322
Dividend per Share 2 0.7100 0.7300 0.7300 0.7300 0.7300 0.7500 0.7500 0.7500 0.7500 0.7700 0.7650 0.7650 0.7650 0.7633 0.7633
Announcement Date 2/1/22 4/28/22 8/2/22 10/27/22 2/2/23 4/27/23 8/3/23 11/7/23 2/6/24 4/25/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 241 30,879 27,449 18,845 17,723 18,152 12,685 7,537
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.0193 x 2.342 x 1.88 x 1.319 x 1.345 x 1.89 x 0.9093 x 0.5348 x
Free Cash Flow 1 8,319 7,518 10,805 8,344 7,421 8,359 9,732 10,043
ROE (net income / shareholders' equity) 38.3% 43.8% 46.8% 43.3% 38.5% 21.9% 38.8% 34.7%
ROA (Net income/ Total Assets) 8.6% 0.19% 9.13% 14% 13.5% 4.32% 13% 13%
Assets 1 62,651 65,079 68,180 32,874 41,980 9,348 48,751 52,486
Book Value Per Share 2 17.80 14.40 16.80 17.00 18.10 15.90 19.10 21.50
Cash Flow per Share 2 7.160 6.470 9.020 7.190 6.360 3.170 7.840 8.350
Capex 1 825 650 579 728 585 628 672 683
Capex / Sales 3.67% 2.63% 2.12% 2.67% 2.16% 2.28% 2.4% 2.38%
Announcement Date 2/4/20 2/4/21 2/1/22 2/2/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Gilead Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.65 USD
Average target price
82.93 USD
Spread / Average Target
+22.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-16.49% 84.28B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.35% 588B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.42% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.02% 326B
ABBVIE INC. Stock AbbVie Inc.
+4.27% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.53% 239B
NOVARTIS AG Stock Novartis AG
+10.16% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-8.14% 200B
AMGEN INC. Stock Amgen Inc.
+8.12% 167B
PFIZER, INC. Stock Pfizer, Inc.
-1.42% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Financials Gilead Sciences, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW